A single-center retrospective cohort of 269 breast cancer patients receiving concurrent GLP-1 receptor agonists and adjuvant endocrine therapy was analyzed for weight outcomes at one year. Investigators required initiation of GLP-1 therapy during the study interval and at least one year of overlap with endocrine agents. Medication reconciliation lists and pharmacy dispense records provided exposure data. The primary endpoint was percentage weight change from GLP-1 start to 12 months (±2 months); secondary endpoints were the proportions achieving ≥5%, ≥10%, and ≥15% weight loss.
Data indicated a mean one-year percentage weight loss of −4.5% (95% CI −6.0% to −3.0%), corresponding to a mean absolute loss of −3.9 kg (95% CI −4.96 to −2.93 kg). The cohort-level effect was statistically significant, but substantially lower than the 10–20% weight reductions seen in postmenopausal subgroups of randomized GLP-1 trials (comparison p < 0.001, as reported by the authors). Only 21.3% of patients reached ≥10% weight loss and 10.4% reached ≥15% weight loss at one year.
The study team observed statistically significant differences in weight trajectory by GLP-1 agent (p = 0.003). Reported one-year percentage changes were −5.8% with semaglutide, −4.7% with tirzepatide, and +0.1% with dulaglutide. The authors noted that dulaglutide is approved for type 2 diabetes only, a detail relevant when comparing expected weight effects across agents. These agent-level differences suggest choice of GLP-1 RA influenced outcomes within this population.
Seventy point six percent of the cohort had type 2 diabetes mellitus. The investigators reported that T2DM status was not significantly associated with overall weight loss on t-test (p = 0.288). Despite that, patients without T2DM were numerically more likely to achieve ≥15% weight loss (21.5% vs 5.8%), an observation the authors presented descriptively.
Baseline weight correlated with absolute weight loss (r = −0.19, p = 0.002), meaning heavier patients tended to lose more kilograms, though percentage weight loss did not differ significantly across baseline BMI categories (p = 0.303). Hormone receptor biology also showed an association: PR-negative patients lost more weight than PR-positive patients (−8.2% vs −4.2%; p = 0.021, effect size d = 0.46), according to the reported data.
Investigators performed a retrospective review at a single academic center. Inclusion criteria required documented initiation of a GLP-1 RA and at least one year of concurrent endocrine therapy. The team used electronic medication reconciliation lists and pharmacy dispensing reports to ascertain exposure. The primary outcome was percentage body weight change at approximately 12 months after GLP-1 initiation, with pre-specified secondary categorical thresholds for clinically relevant weight loss (≥5%, ≥10%, ≥15%).
The abstract supplies cohort size, mean percent and absolute weight changes with 95% confidence intervals, agent-specific differences, correlation coefficients, and p-values for key comparisons. It does not present details about dosing regimens, titration schedules, adherence measures, or exact endocrine-therapy agents and durations beyond class-level references. Those methodological specifics were not reported in the abstract.
Authors stated that GLP-1 receptor agonists produced statistically significant but attenuated weight loss in breast cancer patients receiving concurrent endocrine therapy. The analysis was retrospective and single-center, which limits causal inference and generalizability. The abstract does not include dosing details, adherence data, or granular endocrine-therapy regimens; those omissions constrain interpretation of agent effects and mechanistic pathways.
Given the observed attenuation compared with randomized obesity trials and the agent-specific differences, the authors recommended prospective trials to evaluate efficacy and to explore potential oncologic interactions. The paper notes emerging evidence of oncologic benefit as rationale, but prospective randomized data in breast cancer patients on endocrine therapy are needed to define optimal agent selection, dosing strategies, and the interplay of metabolic and hormonal modifiers.